salvage

ibalizumab HIV

Ibalizumab: First Long Acting HIV Treatment Available Now Via Expanded Access

Blogger /

No one can deny that many patients can now suppress their HIV with effective antiretrovirals (ARVs) that cause fewer side effects. However, a vulnerable and often forgotten minority of people are still struggling with multi-drug resistant HIV (MDR-HIV) while they anxiously wait for access to lifesaving ARVs that would finally control their viral replication. Although […]

Ibalizumab: First Long Acting HIV Treatment Available Now Via Expanded Access Read More »

WORLD AIDS DAY: Time to Help Victims of HIV Drug Studies and Resistance

Leave a Comment / Blogger, Uncategorized /

We have repeatedly heard the following statements about multi-drug resistant HIV (MDR-HIV) patients in a host of meetings on treatment access and HIV research: “These patients no longer exist – they’re either dead or have responded to the latest ARVs”; “Only patients who do not adhere to their HIV regimens have MDR-HIV”; and “Our clinic cannot provide expanded access programs (EAPs) due

WORLD AIDS DAY: Time to Help Victims of HIV Drug Studies and Resistance Read More »

PoWeR Resources

Leave a Comment / Blogger, Uncategorized /

I wanted to remind everyone about resources from Program for Wellness Restoration (PoWeR). Regards, Nelson Vergel Director Sites: https://www.powerusa.org/ https://www.facialwasting.org/ https://www.testosteronewisdom.com/ https://www.agingwithhiv.org/ https://www.salvagetherapies.org/ Groups: https://www.facebook.com/groups/testosteronereplacement/  https://health.groups.yahoo.com/group/PozHealth/  https://www.facebook.com/groups/egrifta/ https://www.facebook.com/HIVCure  https://www.facebook.com/PoWeRUSA  Ask questions: https://www.thebody.com/Forums/AIDS/Aging/ask.html  Twitter:  https://twitter.com/#!/nelsonvergel Doctor’s Lists, Directories, Compounding pharmacy, etc: https://powerusa.org/resources.html Upcoming: ShortcuttoShape.com

PoWeR Resources Read More »

ViiV Announces Expanded Access of New Integrase Inhibitor…But Activists Are Concerned About Its Potential Misuse

Leave a Comment / Blogger, Uncategorized /

The dolutegravir expanded access program (EAP) has been designed to provide free access to Shionogi-ViiV Healthcare’s investigational integrase inhibitor, dolutegravir (DTG, S/GSK1349572) in an open-label protocol program to adults living with HIV who have documented raltegravir or elvitegravir resistance, who have limited treatment options, and who require DTG to construct a viable antiretroviral regimen for

ViiV Announces Expanded Access of New Integrase Inhibitor…But Activists Are Concerned About Its Potential Misuse Read More »

Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program

Leave a Comment / Blogger, Uncategorized /

FOR IMMEDIATE RELEASE: February 9, 2012 Contact: Nelson Vergel ([email protected]) Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program New York, February 9, 2012—AIDS activists and physician advocates welcome the news that ViiV Healthcare will be providing  expanded access of dolutegravir (DTG), a new investigational integrase inhibitor for HIV patients with

Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program Read More »

For Doctors: How You Can Help Your Patients Who Are Running Out of HIV Treatment Options

Leave a Comment / Blogger, Uncategorized /

By Nelson Vergel, B.S.Ch.E., M.B.A. July 6, 2011 In a previous blog post, I reviewed the current situation for the minority of patients with HIV who have run out of treatment options. Of the HIV medications in development with potential activity against highly resistant HIV (i.e., patients with GSS=0), two may become available within the next

For Doctors: How You Can Help Your Patients Who Are Running Out of HIV Treatment Options Read More »

GSK- ViiV start their phase 3 study for their second generation integrase inhibitor (dolutegravir) in raltegravir experienced patients

Leave a Comment / Blogger, Uncategorized /

https://clinicaltrials.gov/ct2/show/NCT01328041?term=dolutegravir&rank=1 For more on dolutegravir: Report from CROI 2011 Dr Joe Eron presented new dosing and efficacy phase 2b data on the new GSK integrase inhibitor dolutegravir (DTG, S/GSK1349572) using 50 mg twice a day in patients whose HIV virus has developed resistance to raltegravir (Isentress). Prior data presented in Vienna from a cohort (cohort

GSK- ViiV start their phase 3 study for their second generation integrase inhibitor (dolutegravir) in raltegravir experienced patients Read More »

Dolutegravir, Trii and new abacavir data- How it all ties together

Leave a Comment / Blogger, Uncategorized /

By Nelson Vergel Powerusa.org Dr Joe Eron presented new dosing and efficacy phase 2b data on the new GSK integrase inhibitor dolutegravir (DTG, S/GSK1349572) using 50 mg twice a day in patients whose HIV virus has developed resistance to raltegravir (Isentress). Prior data presented in Vienna from a cohort (cohort 1) of patients who took

Dolutegravir, Trii and new abacavir data- How it all ties together Read More »

New Drugs and New Combinations – How will They Change What We Do?

Leave a Comment / Blogger, Uncategorized /

IAC Summary on New Drugs and New Combinations – How will They Change What We Do?  Vienna July 18-23 2010 Joe Eron, Univ of North Carolina This year’s IAC was one of the most exciting and data-filled International AIDS meetings since Vancouver in 1996.  The defining presentation of the meeting was the CAPRISA 004 study that

New Drugs and New Combinations – How will They Change What We Do? Read More »